시장보고서

상품코드

1553702

독소루비신 시장 규모, 점유율 및 동향 분석 보고서 : 제형별, 용도별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 80 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

독소루비신 시장 성장 및 동향 :

Grand View Research의 최신 보고서에 따르면, 세계 독소루비신 시장 규모는 2030년까지 15억 3,000만 달러에 달하고, 예측 기간 동안 6.6%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

약물 부족을 억제하기 위해 시장 진출기업 증가는 향후 몇 년동안 시장을 주도할 것으로 예상되는 중요한 요인 중 하나입니다. 독소루비신 제조업체로는 Ortho Biotech Products, LP, Ben Venue Laboratories, Inc, Bristol-Myers Squibb Company 등이 있으며, AIDS 관련 카포시 육종, 다발성 골수종, 신경아세포종, 골육종, 난소암 등 다양한 용도의 독소루비신 제제를 생산하고 있습니다. 난소암 등 다양한 적응증에 대한 독소루비신 제제의 적응증 증가가 수요 증가를 견인하고 있습니다. 건강에 미치는 악영향을 극복하기 위한 약물 제제의 기술적 진보와 나노입자 및 리포좀 코팅과 같은 다양한 유형의 약물 전달 시스템의 도입은 업계 성장을 가속하는 매우 중요한 요인 중 일부입니다.

미국 정부는 미국 지역 내 생명유지제, 화학요법제 및 긴급히 필요한 약품의 부족을 극복하기 위한 행정명령을 발표했으며, 2016년 예상 SEER(Surveillance, Epidemiology, and End Results) 추산에 따르면, 2016년 예상 악성 종양 환자 수는 다음과 같습니다.

백혈병 60,140명
유방암 2,46,660명
자궁내막암 60,050명
위암 26,370명
간암 39,230명
신장암 62,700명

2016년 백혈병 림프종 협회의 추산에 따르면 약 60,140명이 백혈병 진단을 받을 것으로 예상됩니다. 유병률 증가와 그에 따른 생존율 증가는 기술 발전과 새로운 치료 방법의 확대 채택을 나타내는 요인 중 하나입니다.

독소루비신 시장 보고서 하이라이트

2023년 독소루비신 시장의 가장 큰 용도는 유방암입니다. 시스플라틴과의 병용요법에서 독소루비신에 대한 수요 증가는 독소루비신 시장을 견인할 것으로 예상되는 매우 중요한 요인 중 하나입니다.
예측 기간 동안 방광암 분야는 높은 CAGR로 성장할 것으로 예상됩니다. 진행성 방광암의 표준 치료제인 독소루비신은 여전히 방광암 관리에 있어 중요한 요소입니다.
2023년 북미는 전 세계 독소루비신 시장에서 37.7% 이상 시장 점유율을 차지할 것으로 예상됩니다. 존슨앤드존슨(Johnson & Johnson), 선 파마슈티컬스 인더스트리즈(Sun Pharmaceuticals Industries Ltd.)와 같은 유력한 시장 기업의 존재와 효과적인 대체 약물에 대한 인식이 높아진 것이 이 지역의 높은 시장 점유율의 주요 요인으로 작용하고 있습니다.
아시아태평양은 이 시장에서 가장 빠르게 성장하는 지역입니다. 항암제 치료에 대한 미충족 수요가 존재하고 중국, 일본, 인도 등의 국가에서 빠르게 성장하고 있는 제약 산업은 향후 몇 년동안 시장을 주도할 것으로 예상되는 요인 중 하나입니다.

독소루비신 시장 점유율, 지역별, 2023년 및 2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카공화국
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업의 최근 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 개요
- Pfizer Inc.
- Johnson &Johnson Services, Inc.
- Sun Pharmaceutical Industries Ltd
- Cipla.
- Cadila Pharmaceuticals.
- Novartis AG
- Dr. Reddy's Laboratories Ltd.
- SRS Life Sciences
- MicroBiopharm Japan Co., Ltd.
- Baxter

LSH 24.09.26

Doxorubicin Market Growth & Trends:

The global doxorubicin market size is expected to reach USD 1.53 billion by 2030, registering a CAGR of 6.6% during the forecast period, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

Leukemia 60,140
Breast cancer 2,46,660
Endometrial cancer 60,050
Gastric cancer 26,370
Liver cancer 39,230
Kidney Cancer 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Doxorubicin Market Report Highlights:

In 2023, breast cancer is the largest application of doxorubicin market. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.
Bladder cancer segment projected to grow at a significant CAGR during the forecast period. Doxorubicin, which has been a standard treatment for advanced bladder cancer, remains a critical component in the management of the disease.
In 2023, North America held majority of market share of over 37.7% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.
Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Doxorubicin Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Doxorubicin Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Doxorubicin Market: Drug Formulation Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Doxorubicin Market: Drug Formulation Movement Analysis, 2023 & 2030 (USD Million)
4.3. Lyophilized Powder
- 4.3.1. Lyophilized Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Doxorubicin Injection
- 4.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Doxorubicin Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Doxorubicin Market: Application Analysis, 2023 & 2030 (USD Million)
5.3. Bladder Cancer
- 5.3.1. Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Kaposi Sarcoma
- 5.4.1. Kaposi Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Leukemia
- 5.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Lymphoma
- 5.6.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
- 6.3.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Doxorubicin Market: Regional Estimates & Trend Analysis

7.1. Doxorubicin Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.K.
  - 7.3.2.1. U.K. Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific
- 7.4.2. Asia Pacific Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Japan
  - 7.4.4.1. Japan Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. India
  - 7.4.5.1. India Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Australia
  - 7.4.7.1. Australia Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.8. Thailand
  - 7.4.8.1. Thailand Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. UAE Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Pfizer Inc.
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Johnson & Johnson Services, Inc.
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Sun Pharmaceutical Industries Ltd
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Cipla.
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Cadila Pharmaceuticals.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Novartis AG
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Dr. Reddy's Laboratories Ltd.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. SRS Life Sciences
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. MicroBiopharm Japan Co., Ltd.
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Baxter
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

독소루비신 시장 규모, 점유율 및 동향 분석 보고서 : 제형별, 용도별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

독소루비신 시장 성장 및 동향 :

독소루비신 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 독소루비신 시장 변수, 동향, 범위

제4장 독소루비신 시장 : 제형별 추정·동향 분석

제5장 독소루비신 시장 : 용도별 추정·동향 분석

제6장 독소루비신 시장 : 유통 채널별 추정·동향 분석

제7장 독소루비신 시장 : 지역별 추정·동향 분석